![outline29797](http://s1.studyres.com/store/data/002851705_1-410d825141077f78f2a33268d820a426-300x300.png)
outline29797
... The prevalence of rubeosis iridis among patients with diabetes mellitus ranges from 0.2520%, with neovascular glaucoma developing in approximately 13-41% of these patients. Neovascular glaucoma can develop within weeks to years after neovascularization of the iris is first noted, although diabetes u ...
... The prevalence of rubeosis iridis among patients with diabetes mellitus ranges from 0.2520%, with neovascular glaucoma developing in approximately 13-41% of these patients. Neovascular glaucoma can develop within weeks to years after neovascularization of the iris is first noted, although diabetes u ...
Cancer treatment in the Arab-Islamic medicine: Integration of
... without appointing a remedy for it, with the exception of one disease, agedness.", "Allah has sent down both the disease and the cure, and He has appointed a cure for every disease, so treat yourselves medically", "The one who sent down the disease sent down the remedy", "For every disease, Allah ha ...
... without appointing a remedy for it, with the exception of one disease, agedness.", "Allah has sent down both the disease and the cure, and He has appointed a cure for every disease, so treat yourselves medically", "The one who sent down the disease sent down the remedy", "For every disease, Allah ha ...
Formulary Decisions August-September 2015
... receptor-targeted agents. SMC restriction: to use in combination with paclitaxel. The addition of bevacizumab to chemotherapy improved progression free survival in patients with platinum-resistant ovarian cancer in an open-label phase III randomised study. This SMC advice takes account of the benefi ...
... receptor-targeted agents. SMC restriction: to use in combination with paclitaxel. The addition of bevacizumab to chemotherapy improved progression free survival in patients with platinum-resistant ovarian cancer in an open-label phase III randomised study. This SMC advice takes account of the benefi ...
CLR 131 - Cellectar Biosciences
... cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference i ...
... cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference i ...
Chronic Visual Loss
... • He has not reported any problems with vision, but the test report shows a reduction in peripheral vision in the RE ...
... • He has not reported any problems with vision, but the test report shows a reduction in peripheral vision in the RE ...
Pharmacologic insights into the future of trastuzumab
... Pharmacokinetics of trastuzumab i.v. until disease progression with (n = 46) or without Humanization of the murine monoclonal antibody 4D5 cisplatin 75 mg/m2 every four weeks (n = 39) produced to produce trastuzumab resulted in a molecule with in similar results [22, 23]. In the single-agent trial, ...
... Pharmacokinetics of trastuzumab i.v. until disease progression with (n = 46) or without Humanization of the murine monoclonal antibody 4D5 cisplatin 75 mg/m2 every four weeks (n = 39) produced to produce trastuzumab resulted in a molecule with in similar results [22, 23]. In the single-agent trial, ...
Age-Related Macular Degeneration - Fact Sheet
... Amsler grid: Contact your local CNIB office or visitcnib.ca to obtain a copy of this simple test, which can be done at home. Treatment There is currently no treatment for dry AMD. A special formulation of ocular vitamins for intermediate dry AMD can lower the risk of developing an advanced conditi ...
... Amsler grid: Contact your local CNIB office or visitcnib.ca to obtain a copy of this simple test, which can be done at home. Treatment There is currently no treatment for dry AMD. A special formulation of ocular vitamins for intermediate dry AMD can lower the risk of developing an advanced conditi ...
Clinical study on eye metastasis in patients with breast cancer
... with less toxicity. The receptor tyrosine kinase CerBb2, also known as human epidermal growth factor receptor 2 (HER2), has also become an important target because it is over expressed in up to 20%--30% of breast cancer patients. Trastuzumab is a humanized monoclonal antibody that binds to the extr ...
... with less toxicity. The receptor tyrosine kinase CerBb2, also known as human epidermal growth factor receptor 2 (HER2), has also become an important target because it is over expressed in up to 20%--30% of breast cancer patients. Trastuzumab is a humanized monoclonal antibody that binds to the extr ...
Long-term Relationship of Ovulation
... Among the analytic cohort of 9,892 women, the mean age at first evaluation for infertility was 30.1 years. During a median of 30.0 years of follow-up, 749 breast cancers were identified among study participants, with a mean age at diagnosis of 52.7 years. The identified risk factors for breast cance ...
... Among the analytic cohort of 9,892 women, the mean age at first evaluation for infertility was 30.1 years. During a median of 30.0 years of follow-up, 749 breast cancers were identified among study participants, with a mean age at diagnosis of 52.7 years. The identified risk factors for breast cance ...
Age-Related Macular Degeneration
... Many Americans must live with vision loss from AMD. The NIH’s low vision research program supports the development of low-vision aids and rehabilitation strategies to help patients maintain independence and mobility. Additionally, the National Eye Health ...
... Many Americans must live with vision loss from AMD. The NIH’s low vision research program supports the development of low-vision aids and rehabilitation strategies to help patients maintain independence and mobility. Additionally, the National Eye Health ...
DRUG NAME: Cetuximab
... Topical retinoids or benzoyl peroxide may worsen the condition and should be avoided.14 Very be required. rare cases of skin necrosis have been reported. Limit sun exposure during treatment and for 2 months following cessation of treatment.2 Hair alterations are typically a delayed effect, occurring ...
... Topical retinoids or benzoyl peroxide may worsen the condition and should be avoided.14 Very be required. rare cases of skin necrosis have been reported. Limit sun exposure during treatment and for 2 months following cessation of treatment.2 Hair alterations are typically a delayed effect, occurring ...
Clinical Endpoints for Retinal disorders
... business of retina clinical trials for the retina specialist ...
... business of retina clinical trials for the retina specialist ...
Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian
... and neck, endometrium, or bladder, who often receive treatment with platinum derivatives. In 1998, cancers at these sites were diagnosed in approximately 325,000 patients in the United States.4 A proportion of these patients may have been eligible for platinum-based chemotherapy with or without radi ...
... and neck, endometrium, or bladder, who often receive treatment with platinum derivatives. In 1998, cancers at these sites were diagnosed in approximately 325,000 patients in the United States.4 A proportion of these patients may have been eligible for platinum-based chemotherapy with or without radi ...
Targeting the androgen receptor in the
... after docetaxel treatment [cou-aa-301 (search for NCT00638690 at http://clinicaltrials.gov)]. The study was unblinded after the first interim analysis demonstrated an improvement in overall survival by approximately 4 months for the aa–prednisone group [14.8 months vs. 10.9 months; hazard ratio (hr) ...
... after docetaxel treatment [cou-aa-301 (search for NCT00638690 at http://clinicaltrials.gov)]. The study was unblinded after the first interim analysis demonstrated an improvement in overall survival by approximately 4 months for the aa–prednisone group [14.8 months vs. 10.9 months; hazard ratio (hr) ...
Author Affiliations: fluorescent scars along the arcades of the left eye
... (the hemoglobin A1c level was 6.8% of total hemoglobin 6 months prior to hospitalization [to convert to proportion of total hemoglobin, multiply by 0.01]). Visual acuity of 20/40 OD was attributed to the mild cataract. The macular edema was treated with topical nepafenac in the right eye, 4 times da ...
... (the hemoglobin A1c level was 6.8% of total hemoglobin 6 months prior to hospitalization [to convert to proportion of total hemoglobin, multiply by 0.01]). Visual acuity of 20/40 OD was attributed to the mild cataract. The macular edema was treated with topical nepafenac in the right eye, 4 times da ...
Lung Cancer - American Cancer Society
... potential harms of lung cancer screening. Screening should only be done at facilities that have: The right type of CT scan Experience in using low-dose CT scans for lung cancer screening A team of specialists that can provide the appropriate care and follow-up of patients with abnormal scans. ...
... potential harms of lung cancer screening. Screening should only be done at facilities that have: The right type of CT scan Experience in using low-dose CT scans for lung cancer screening A team of specialists that can provide the appropriate care and follow-up of patients with abnormal scans. ...
Chemoprevention_review_final_revision_HMW_edit_title
... new treatments. Put simply, newer cancer treatments are expensive. For example, the tyrosine kinase inhibitor, Ponatinib, used for treatment of chronic myeloid leukaemia costs approximately $140,000 (USD) per patient per year 2. The average course of cancer treatment with a non-hormonal drug cost 34 ...
... new treatments. Put simply, newer cancer treatments are expensive. For example, the tyrosine kinase inhibitor, Ponatinib, used for treatment of chronic myeloid leukaemia costs approximately $140,000 (USD) per patient per year 2. The average course of cancer treatment with a non-hormonal drug cost 34 ...
Orthomolecular - Jeffrey Dach MD
... lie anywhere on that curve below the level of detection. If they are already up that curve preventive doses are going to slow the rate of growth but not keep the cancer from breaking through into the detectable range. ...
... lie anywhere on that curve below the level of detection. If they are already up that curve preventive doses are going to slow the rate of growth but not keep the cancer from breaking through into the detectable range. ...
Treatment of Metastatic Renal Cell Carcinoma
... Given the substantial toxicity of high-dose IL-2, interest shifted to utilizing lower doses in the metastatic setting. Based on promising results of phase II trials, two phase III trials were undertaken [13, 14]. The first trial compared high-dose (720,000 IU/kg, n = 156) or low-dose (72,000 IU/kg, ...
... Given the substantial toxicity of high-dose IL-2, interest shifted to utilizing lower doses in the metastatic setting. Based on promising results of phase II trials, two phase III trials were undertaken [13, 14]. The first trial compared high-dose (720,000 IU/kg, n = 156) or low-dose (72,000 IU/kg, ...
Idiopathic Choroidal Neovascularization
... by this procedure. A blind spot corresponding to the site of laser is a side effect of this form of treatment. If the blood vessel is growing under the center, or close to the center, then an injection of a drug called bevacizumab (brand name Avastin) may be given into the vitreous.(1;2) The eye is ...
... by this procedure. A blind spot corresponding to the site of laser is a side effect of this form of treatment. If the blood vessel is growing under the center, or close to the center, then an injection of a drug called bevacizumab (brand name Avastin) may be given into the vitreous.(1;2) The eye is ...
Ocular toxicity of systemic anticancer chemotherapy
... Consequently the ophthalmologist is seeing more patients with adverse ocular side effects secondary to these antineoplastic agents. Ocular toxicity induced by cancer chemotherapy includes a broad spectrum of disorders, reflecting the unique anatomical, physiological and biochemical features of the e ...
... Consequently the ophthalmologist is seeing more patients with adverse ocular side effects secondary to these antineoplastic agents. Ocular toxicity induced by cancer chemotherapy includes a broad spectrum of disorders, reflecting the unique anatomical, physiological and biochemical features of the e ...
The New Generation of Targeted Therapies for
... erlotinib. Much like gefitinib, erlotinib is orally active and was well tolerated in phase I trials.[ 1,16] An open-label phase II trial of erlotinib in metastatic breast cancer was recently completed.[17] Two cohorts of patients were accrued to this study. The first cohort of 47 patients was requir ...
... erlotinib. Much like gefitinib, erlotinib is orally active and was well tolerated in phase I trials.[ 1,16] An open-label phase II trial of erlotinib in metastatic breast cancer was recently completed.[17] Two cohorts of patients were accrued to this study. The first cohort of 47 patients was requir ...
Evidence base of the effects of smoking on the eye
... Leber’s optic neuropathy (Tsao et al. Br J Ophthalmol 1999;83:577-81) Non-arteritic ischemic optic neuropathy (Chung et al. Ophthalmology 1994;101:779-82) ...
... Leber’s optic neuropathy (Tsao et al. Br J Ophthalmol 1999;83:577-81) Non-arteritic ischemic optic neuropathy (Chung et al. Ophthalmology 1994;101:779-82) ...
Conventional Cancer Treatment
... Nitrogen mustards were the first clinically useful anticancer agents [1] and its derivatives, such as cyclophosphamide, are still among the most widely used antitumor drugs [2]. Cyclophosphamide is a derivative of nitrogen mustards with a modified chemical structure that confers it a greater specifi ...
... Nitrogen mustards were the first clinically useful anticancer agents [1] and its derivatives, such as cyclophosphamide, are still among the most widely used antitumor drugs [2]. Cyclophosphamide is a derivative of nitrogen mustards with a modified chemical structure that confers it a greater specifi ...